Pay in 4 interest-free payments of $7.37 Learn more
Ships within 48 hours · Estimated delivery Sep 6 - Sep 11
Developed by Eli Lilly, retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors a novel mechanism that distinguishes it from existing licensed weight management medicines
Enferm Infecc Microbiol Clin
VK0214, oral TR agonist for X-linked adrenoleukodystrophy (X-ALD) Recent Highlights: In June 2026, Viking announced that its working toward maintenance-dosing data for subcutaneous VK2735 and preparing to start Phase 3 trials of the oral tablet in Q4 2026, with the goal of becoming the first company to offer a dual GLP-1/GIP agonist in both oral and injectable form
PMID: 40573261
US$ 21.19
US$ 28.86
US$ 23.64
